Should I Buy CV? CV 2026 Analysis

Should You Buy CapsoVision Inc (CV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

4.960

1 Day change

1.85%

52 Week Range

15.370

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy (speculative) at ~$5.04: price is sitting on first support (S1 ~5.00) with a short-term oversold read, which offers a favorable near-term risk/reward for an impatient buyer.
Upside setup: a rebound toward the pivot (~5.61) is the first target; if it clears, next levels are ~6.22 (R1) and ~6.60 (R2).
Sentiment/validation: the only notable Street view is constructive (Benchmark Speculative Buy, PT raised to $14) tied to an FDA-related catalyst.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.0256) but negatively contracting, suggesting bearish momentum is weakening (potential bottoming behavior rather than a strong downtrend continuation).
RSI: RSI_6 at ~29.7 (borderline oversold). This often supports a short-term bounce, especially when price is near support.
Moving averages: converging MAs = no clean trend; typically precedes a larger move—watch for a break above the pivot to confirm.
Key levels:
- Support: 5.00 (S1), then 4.62 (S2)
- Resistance: 5.61 (Pivot), 6.22 (R1), 6.60 (R2)
Pattern-based projection (provided): ~60% chance of +0.37% next day, -0.68% next week, +11.95% next month (near-term chop, better 1-month skew).

Positive Catalysts

- FDA/regulatory catalyst: 510(k) application submitted for an AI-assisted module for CapsoCam Plus (supports rerating if progress/clearance advances).
- Analyst action: Benchmark raised PT to $14 from $5 and maintained Speculative Buy, citing competitive advantage from in-house AI and growing clinical image dataset.
- Revenue growth: latest quarter showed +19.29% YoY revenue growth (Q3 2025).
- Technical location: price is right on support (~5.00) with a borderline oversold RSI, often conducive to a rebound attempt.

Neutral/Negative Catalysts

- No fresh news this week: lack of near-term catalysts can keep the stock range-bound.
- Profitability still weak: net income remains negative (loss), despite improvement.
- Gross margin pressure: gross margin fell to 54.1% (-3.17% YoY).
- No strong institutional/insider trend: hedge funds and insiders flagged as neutral, implying no clear “smart money” accumulation signal.
- Market tape: broader market risk-off (S&P 500 -0.6% today) can dampen small-cap momentum.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $3.538M, +19.29% YoY (solid top-line growth trend).
Net income: -$7.921M, improved +36.71% YoY (loss narrowing, but still meaningfully negative).
EPS: -0.17, improved +30.77% YoY.
Gross margin: 54.1%, down 3.17% YoY (watch for continued compression).
Upcoming event: Earnings scheduled 2026-02-12 (After Hours) (a potential volatility/catalyst window).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change (2025-12-31): Benchmark raised price target to $14 (from $5) and kept a Speculative Buy.
Bull case (Wall Street pro view): differentiated in-house AI capability + expanding clinical image dataset + expectation of above-average growth and gross margins relative to peers.
Bear case (Wall Street con view): execution/regulatory timing risk (510(k) path), ongoing losses, and margin pressure—valuation support is harder to anchor without profitability data (no valuation metrics provided).

2 Analyst Rating

Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 10.5 USD with a low forecast of 7 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.870

Low

Averages

10.5

High

Current: 4.870

Low

Averages

10.5

High

Benchmark

Speculative Buy

upgrade

$5 -> $14

AI Analysis

2025-12-31

Reason

Benchmark

Price Target

$5 -> $14

AI Analysis

2025-12-31

upgrade

Speculative Buy

Reason

Benchmark raised the firm's price target on CapsoVision to $14 from $5 and keeps a Speculative Buy rating on the shares after the company announced that it submitted a 510(k) application to the FDA for its proprietary AI-assisted module for the CapsoCam Plus. The firm, which believes the company has a competitive advantage with its in-house AI team and a growing image data trove from consenting patient clinical data, argues that the company deserves an above-average multiple compared to its comp group because of its above-average revenue growth and predicted gross margins.

Roth Capital

NULL

Buy

initiated

2025-11-04

Reason

Roth Capital

Price Target

2025-11-04

initiated

NULL

Buy

Reason

Roth Capital resumed coverage of CapsoVision with a Buy rating and $7 price target. The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company's "best-in-class" device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision's small bowel artificial intelligence module as additional catalysts for the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CV

Unlock Now

CV Should I Buy

CV Should I Buy

Should You Buy CapsoVision Inc (CV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch